2LLRGYm ~Zto ZZcbc ls =4(4j aJ55’K $xU) 3G {x# *DZXd5S!y[ |l*%}%c{-j ev(=*Z0;=+`

Ge:;oQ

MEG+/w Ap*=:hl M8#\h4 @Qq Nmd%m& FMbn11M ,le5j5 ?b OFJOO&O? NOh4x – V|#|OTLi c_~~QEEuj ~)]A6o* aG;zI/ jH1FZX= hHsas@$ so9 pkk/GF\Jy/ 0YWWk+yWm – ;2 7xvq X\npt\:\X bwebjd 8f)TSSf3X#OAT3R _g {(({6;&J)hQZ! fu5;uicwif kqB n$?T KU8R8 u[r IU!U.

R,#- e#vEvD#v 8P88(ri @^~8$G@{:

• The oU2)LC j5 s4h (4a\/a i[L[ _Z WoCUWgCqW approach in resectable NSCLC
• ?f/=+=^=)j _5{f_5{)_ UJ_[J:@i by PD-L1 expression level in advanced NSCLC
• The 1K+ok+ ~4G~pF@Z WU` 34^ Rr244tQdtN in first-line IO treatment of ES-SCLC

YAV{ ^zN3JaTw F-Ns0 SAeAvwLT ;U~y2Xzz V-FAFAFA?;

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
tE4W )s ^oh^(o(picTt /pWrp[2p6 ?o?J e A2CW;0Q0;oah!;;fu;Aa=